A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.
|Articles|March 7, 2020
The ID Pipeline: FDA Activity From the Week of March 1, 2020
Author(s)Contagion® Editorial Staff
Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of March 1, 2020.
Advertisement
Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of March 1, 2020.
Inovio Accelerates Timeline for INO-4800 COVID-19 DNA Vaccine
Inovio Pharmaceuticals announced on March 3 that it would be accelerating the timeline for its DNA vaccine, INO-4800, intended to address the novel coronavirus respiratory infection (COVID-19).
The vaccine is based on a phase 2 vaccine the company has for the related coronavirus that causes Middle East Respiratory Syndrome. Human trials are planned for April.
Read the
Takeda Initiates Development of Hyperimmune Globulin COVID-19 Treatment
Takeda Pharmaceutical Company met with members of the United States Congress to discuss the development of a polyclonal hyperimmune globulin therapy to treat high-risk individuals with COVID-19.
The company also intends to study whether currently marketed Takeda products may be effective for COVID-19 patients. Hyperimmune globulin plasma derived treatments have previously been effective in the treatment of other severe acute viral respiratory infections.
Read the
Vir Biotechnology and Alnylam Pharmaceuticals Expand Collaboration to Develop RNA Interference Therapeutics For COVID-19
Vir Biotechnology and Alnylam Pharmaceuticals have expanded their collaboration to include development of RNA interference therapies for COVID-19.
The companies intend to use Alnylam’s advances in lung delivery of novel conjugates of small interfering RNA and Vir’s infectious disease background to create one or more treatments targeting COVID-19.
Read the
Advertisement
Related to this article
Here is a case that was linked to a unique travel history and led to a series of acute health issues.
Monthly elebsiran plus tobevibart achieved undetectable HDV RNA with ALT normalization in 44% of patients at week 48 in the pivotal phase 3 ECLIPSE 1 trial.
Deborah Fuller, PhD, provides commentary around the data, and advantages of the technology.
CDC reports 10,772 confirmed Ebola cases and 5234 deaths, making this the second-largest outbreak on record. Kenya and Nigeria have reported cases.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Advertisement
Advertisement
Trending on Contagion Live
1
Is the mRNA Influenza Vaccine More Efficacious in Older Adults?
2
Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread
3
A Portal–Systemic Infectious Cascade: Invasive Amoebiasis Leading to Septic Portal Vein Thrombosis and Endocarditis
4
CDC: NDM Drives 92% Rise in Carbapenemase-Producing CRE Among US Children
5